RT Journal Article
SR Electronic
A1 Vinall, Phil
T1 MISTIE II Trial: 365-Day Results Demonstrate Improved Outcomes and Cost Benefit
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 1
SP 17
OP 18
DO 10.1177/155989771301004
UL http://mdc.sagepub.com/content/13/1/17.abstract
AB This article presents results from the Minimally Invasive Surgery Plus tPA for Intracerebral Hemorrhage Evacuation trial [MISTIE; NCT00224770], which showed that catheter-based clot reduction plus tissue plasminogen activator (MIS + tPA) is safe and may reduce long-term disability after intracerebral hemorrhage.